<DOC>
	<DOC>NCT01010425</DOC>
	<brief_summary>Double-blind, randomized, placebo and active controlled dose-ascending study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-001 (TransCon PEG hGH).</brief_summary>
	<brief_title>Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Healthy male subjects 20 to 45 years old Body Mass Index of 18.5 kg/m2 and less than or equal to 29.9 kg/m2 Others Known history of hypersensitivity to human growth hormone (hGH) Known history of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, immunological, hepatic or renal disease, or malignancies Others</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>